Literature DB >> 8714170

[Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs].

J F Martí Massó1, J J Poza.   

Abstract

To determine the prevalence, clinical signs and course of drug-induced Parkinsonism (DIP) in a general neurology practice, as well as to study the changing pattern of drugs implicated. Retrospective study of DIP patients seen between January 1981 and December 1993. Of the 306 cases of parkinsonism seen, 56.8% were induced or aggravated by drugs. This side effects is more frequent in women and often occurs in old age. The drugs implicated most often were cinnarizine, sulpiride and flupentixol. Forty-two patients took 2 drugs simultaneously, whereas 6 took 3. The number of DIP seen increased after 1986 and then remained stable through 1993. Between 1981 and 1988, the drug most often implicated was cinnarizine, though its relative impact decreased in later years. The most frequently seen form of presentation was rigidakinetic syndrome. Neither drug nor age influenced clinical presentation. Parkinsonism disappeared completely within a mean of 5 months in 142 (82%) patients. Twenty-eight (16%) developed Parkinson's disease. Six of them were symptom-free for 12 to 72 months (mean 40 months), whereas 22 never experienced relief from parkinsonism. Sixteen suffered tardive dyskinesia, a complication that was not associated with the use of any particular drug. More than half of the cases of parkinsonism seen in a neurology practice are drug induced or aggravated, generally by psychotropic drugs. The frequency has held steady for the past 6 years. The drugs implicated change as knowledge of their inducement of parkinsonism becomes known. The clinical picture is usually reversible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8714170

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  6 in total

1.  Severe parkinsonism under treatment with antipsychotic drugs.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Sermin Toto; Alexandra Neyazi; Barbara Däubl; Susanne Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-23       Impact factor: 5.270

Review 2.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 3.  Drug-induced parkinsonism in the elderly: incidence, management and prevention.

Authors:  José Luis López-Sendón; María Angeles Mena; Justo García de Yébenes
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

4.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

5.  Neuroleptic-induced Parkinsonism: Clinicopathological study.

Authors:  Umar A Shuaib; Ali H Rajput; Christopher A Robinson; Alex Rajput
Journal:  Mov Disord       Date:  2015-12-11       Impact factor: 10.338

6.  Metoclopramide and Levosulpiride Use and Subsequent Levodopa Prescription in the Korean Elderly: The Prescribing Cascade.

Authors:  Youn Huh; Do-Hoon Kim; Moonyoung Choi; Joo-Hyun Park; Do-Young Kwon; Jin-Hyung Jung; Kyungdo Han; Yong-Gyu Park
Journal:  J Clin Med       Date:  2019-09-19       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.